Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10156441 | 0.92 | BACE1 (0.58) | BACE1APP | |
| SCHEMBL10155323 | 0.91 | BACE1 (0.56) | BACE1APP | |
| SCHEMBL10158011 | 0.91 | BACE1 (0.62) | BACE1 | |
| SCHEMBL10157711 | 0.91 | BACE1 (0.65) | BACE1 | |
| SCHEMBL10194237 | 0.90 | BACE1 (0.56) | BACE1 | |
| SCHEMBL10155191 | 0.86 | BACE1 (0.56) | BACE1APP | |
| SCHEMBL10156414 | 0.85 | BACE1 (0.65) | BACE1APP | |
| SCHEMBL10157410 | 0.85 | BACE1 (0.55) | BACE1 | |
| SCHEMBL10155194 | 0.85 | BACE1 (0.55) | BACE1 | |
| SCHEMBL10156434 | 0.85 | BACE1 (0.58) | BACE1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9029358-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8815851-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8815851-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-8653067-B2 | Pharmaceutical composition for treating Alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653067-B2 | Pharmaceutical composition for treating Alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8633188-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-8173642-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173642-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20120022249-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120022249-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120016116-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016116-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885 |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | BACE1 14/4885APP 7/4885 |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885 |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | BACE1 17/4885APP 7/4885 |
| US-20120022249-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885 |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885 |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885APP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.